Over the past few years, a “quiet revolution” has been taking place in therapies for diseases affecting the central nervous system (CNS). With less fanfare than one might expect, the science has advanced, new technologies are being deployed in CNS, and investment capital has been fueling the changes.
2021 promises to be a big year for the CNS market. In this paper, we outline some of our thoughts on why we think that’s the case. Developments during the year ahead are likely to have far-reaching implications, so we speculate on what might happen.
Part 2 of 2. Part 1 is available here.